BWS Financial Has Optimistic Outlook of TriMas Q3 Earnings

Key Points

• BWS Financial has revised its Q3 2025 earnings estimate for TriMas to $0.56 per share, increasing from a previous estimate of $0.52, and maintains a "Buy" rating with a target price of $45.00.
• TriMas reported Q2 earnings of $0.61 per share, exceeding estimates of $0.50, with revenues reaching $274.76 million, significantly higher than the expected $251.18 million.
• The company recently declared a $0.04 quarterly dividend per share, indicative of a dividend yield of 0.4%, with a payout ratio of 17.58%.

TriMas Corporation (NASDAQ:TRS - Free Report) - BWS Financial lifted their Q3 2025 earnings estimates for TriMas in a note issued to investors on Wednesday, July 30th. BWS Financial analyst H. Khorsand now forecasts that the industrial products company will post earnings per share of $0.56 for the quarter, up from their prior estimate of $0.52. BWS Financial currently has a "Buy" rating and a $45.00 target price on the stock. The consensus estimate for TriMas' current full-year earnings is $1.69 per share. BWS Financial also issued estimates for TriMas' FY2025 earnings at $1.99 EPS, Q1 2026 earnings at $0.47 EPS and Q4 2026 earnings at $0.43 EPS.

Separately, Wall Street Zen raised TriMas from a "hold" rating to a "buy" rating in a research note on Sunday, June 1st.

TriMas Stock Up 0.7%

Shares of TRS traded up $0.26 during trading on Friday, reaching $35.26. The company's stock had a trading volume of 110,958 shares, compared to its average volume of 411,814. The company has a fifty day moving average of $28.94 and a two-hundred day moving average of $25.30. TriMas has a twelve month low of $19.33 and a twelve month high of $36.77. The company has a market cap of $1.43 billion, a price-to-earnings ratio of 38.80 and a beta of 0.66. The company has a quick ratio of 1.44, a current ratio of 2.59 and a debt-to-equity ratio of 0.59.

TriMas (NASDAQ:TRS - Get Free Report) last issued its earnings results on Tuesday, July 29th. The industrial products company reported $0.61 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.50 by $0.11. The business had revenue of $274.76 million during the quarter, compared to analysts' expectations of $251.18 million. TriMas had a return on equity of 11.49% and a net margin of 3.83%. The company's revenue for the quarter was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.43 EPS.

Institutional Trading of TriMas

Several institutional investors and hedge funds have recently bought and sold shares of TRS. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of TriMas by 3.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,106 shares of the industrial products company's stock worth $568,000 after acquiring an additional 834 shares in the last quarter. Sterling Capital Management LLC boosted its stake in shares of TriMas by 815.5% in the 4th quarter. Sterling Capital Management LLC now owns 1,300 shares of the industrial products company's stock worth $32,000 after buying an additional 1,158 shares during the last quarter. MetLife Investment Management LLC boosted its stake in shares of TriMas by 5.9% in the 4th quarter. MetLife Investment Management LLC now owns 24,788 shares of the industrial products company's stock worth $610,000 after buying an additional 1,378 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of TriMas by 0.7% in the 1st quarter. Bank of New York Mellon Corp now owns 247,761 shares of the industrial products company's stock worth $5,805,000 after buying an additional 1,664 shares during the last quarter. Finally, State of Wyoming purchased a new position in TriMas in the fourth quarter valued at approximately $50,000. Institutional investors own 99.42% of the company's stock.

Insider Activity

In related news, Director Adrianne Shapira acquired 4,000 shares of the company's stock in a transaction that occurred on Thursday, June 5th. The stock was acquired at an average price of $25.82 per share, for a total transaction of $103,280.00. Following the completion of the acquisition, the director owned 8,476 shares of the company's stock, valued at $218,850.32. This trade represents a 89.37% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Shawn Sedaghat acquired 72,937 shares of the company's stock in a transaction that occurred on Thursday, May 22nd. The stock was bought at an average price of $26.16 per share, with a total value of $1,908,031.92. Following the acquisition, the director directly owned 1,883,758 shares of the company's stock, valued at $49,279,109.28. The trade was a 4.03% increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 848,261 shares of company stock valued at $21,645,007. Company insiders own 14.20% of the company's stock.

TriMas Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, August 12th. Investors of record on Tuesday, August 5th will be paid a $0.04 dividend. This represents a $0.16 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 5th. TriMas's dividend payout ratio is currently 17.58%.

About TriMas

TriMas Corporation engages in the design, development, manufacture, and sale of products for consumer products, aerospace, and industrial markets worldwide. The company operates through Packaging, Aerospace, and Specialty Products segments. The Packaging segment offers dispensing products, such as foaming and sanitizer pumps, lotion and hand soap pumps, beverage dispensers, perfume sprayers, and nasal and trigger sprayers; polymeric and steel caps and closures comprising food lids, flip-top and beverage closures, child resistance caps, drum and pail closures, and flexible spouts; polymeric jar products; integrated dispensers; bag-in-box products; and consumable vascular delivery and diagnostic test components under the Rieke, Taplast, Affaba & Ferrari, Intertech, Omega, and Rapak brands.